A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Efavirenz; Lamivudine; Raltegravir Potassium; Tenofovir

Criteria

Inclusion Criteria:

• Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)

Extension Studies:

• First extension: Patient completed the 48-week base study

• Second extension: Patient completed the first 144-week extension study

Exclusion Criteria:

• Less than 18 years of age

• Individuals who currently do not test positive for HIV